By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- A new study on Biotechnology is now available. According to news reporting originating from Foshan, People's Republic of China, by NewsRx correspondents, research stated, "CH50, a recombinant CBD-HepII polypeptide of human fibronectin, was shown to suppress tumor metastasis in murine hepatocarcinoma and melanoma models. However, the effect of CH50 on human cancer cells is still not clear."
Our news editors obtained a quote from the research from Foshan University, "Here we evaluated the efficiency of CH50 delivered by recombinant adeno-associated virus (rAAV) vector for breast cancer treatment. Infection of the two human breast cancer cell line MDA-MB-231 and MDA-MB-468 with a rAAV2 vector encoding CH50 resulted in secretion of soluble CH50. In vitro rAAV-CH50 transduction inhibited adhesion to ECM molecules, and transwell migration and invasion of breast cancer cells induced by fibronectin. In both breast cancer cells, rAAV-CH50 targeted alpha(V)beta 3 signaling, namely inhibited the expression of alpha(V)beta 3, the activation of FAK, the upregulation of cdc2, and the production and activation of MMP-9 by ECM molecules stimulation. rAAV-mediated tail vein transfusion and stable expression of CH50 in the liver resulted in the long-term presence of CH50 in sera of nude mice. Sustained CH50 expression mediated by rAAV vector suppressed the growth and spontaneous metastasis of orthotopic breast cancer xenograft, experimental metastasis of circulating breast cancer cells, and improved the long-term survival of breast tumor-bearing mice."
According to the news editors, the research concluded: "These findings suggest for the first time that rAAV-CH50 gene therapy may present a novel and promising strategy for treatment against metastatic breast cancer."
For more information on this research see: Adeno-associated virus-mediated expression of recombinant CBD-HepII polypeptide of human fibronectin inhibits metastasis of breast cancer. Breast Cancer Research and Treatment, 2014;143(1):33-45. Breast Cancer Research and Treatment can be contacted at: Springer, 233 Spring St, New York, NY 10013, USA. (Springer - www.springer.com; Breast Cancer Research and Treatment - www.springerlink.com/content/0167-6806/)
The news editors report that additional information may be obtained by contacting Z.H. He, Foshan Univ, Dept. of Immunol, Coll Med, Foshan 528000, People's Republic of China. Additional authors for this research include Z. Lei, Y. Zhen, W. Gong, B. Huang, Y. Yuan, G.M. Zhang, X.J. Wang and Z.H. Feng (see also Biotechnology).
Keywords for this news article include: Asia, Biotechnology, Foshan, Viruses, Oncology, Virology, Treatment, Fibronectins, Breast Cancer, Bioengineering, Women's Health, Serum Globulins, Cancer Gene Therapy, Adeno-Associated Virus, Membrane Glycoproteins, People's Republic of China, Extracellular Matrix Proteins
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC